Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.

Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal administration. The effect of intranasal NAC administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal NAC can be used to treat a condition. In some embodiments, MRS can be used to monitor the effect of intranasal NAC administration or to modify the dosage of intranasal NAC administration to treat a condition.

Abstract: Methods of normalizing amino acid metabolism in subjects on restricted protein diets and supplemental amino acids, using specially formulated amino acids that mimic the absorption and metabolism of naturally occurring proteins, are described.

Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include thiolated nitro fatty acids. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

Abstract: The present invention relates to an application of inhibiting myopia by regulating eye scleral lipid metabolism. The present discloses a new mechanism leading to myopia, i.e., a close relationship between abnormal eye scleral lipid metabolism and myopia, thus revealing a new target for prevention and control of myopia; meanwhile, also provided is an eye drop that can effectively prevent and control myopia while avoiding eye allergies.

Abstract: Provided herein are methods of treating a subject having a visual disorder comprising administering daily to the subject, a dosage of about 0.1 mg to 20 mg of a retinoid compound. In some embodiments, the retinoid compound is 9-cis-retinyl acetate.

Abstract: A method for treatment by boosting an immune system of a subject infected with an immunodeficiency disease, including administering to the subject in need thereof of an anti-pathogenic compound, such that the anti-pathogenic compound uses multiple modes of action against the immunodeficiency disease.

Abstract: An isothiocyanate functional surfactant, wherein the protonated form of the surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.

Abstract: Provided is a means useful for enjoying the physiological action of kaempferol. A plant extract contains 1 mg/g or more of a kaempferol aglycone on a dry-weight basis.

Abstract: The invention discloses particular water-dispersible solid formulation of a cannabinoid or a cannabis extract, wherein they are present in the form of a nanoemulsion, and upon dispersion in water said formulation produces nanoparticles (droplets of a submicron size) with an average size of up to about 500 nm. The present disclosure further relates to methods of making thereof, as well as therapeutic applications in humans for treating disorders and broader application for a range of medical conditions.

Abstract: The present disclosure concerns mesoporous silica nanoparticles (MSNP) functionalized to cross in and out of cells and loaded with one or more therapeutics to provide a vehicle that can effectively provide localized treatment to both intracellular and extracellular space. The MSNPs provide a vehicle for adjunct treatment of periodontitis, being able to provide treatment against the microbes and to the tissue.

Abstract: The present invention relates to a method for treating renal fibrosis.

Abstract: The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed on an aromatase inhibitor. Of particular interest are ER+ cancers that do not harbor a gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene. The provided methods involve the administration of an effective amount of lasofoxifene, a pharmaceutically acceptable salt, prodrug or functional derivative thereof.

Abstract: Disclosed are lipidoid compounds as well as lipidoid nanoparticles comprising such compounds.

Abstract: The present application relates to: an anticoccidial composition comprising violacein, a violacein derivative and/or a salt thereof; and a use thereof. A composition comprising violacein, according to one embodiment, has excellent effects of direct killing of protozoa that can induce coccidiosis, inhibiting the cell penetration of the protozoa and/or inhibiting the intracellular proliferation of the protozoa, and preventing, alleviating, and treating in vivo coccidiosis.

Abstract: The present invention relates to compound of Formula 1 for use in treating IPF, by reducing collagen deposition in lungs, attenuating the fibrotic marker's expression (in IPF cell-lines Bleomycin induced rat lungs) and improving the bleomycin induced pathological changes in rat lungs, and ARDS, by reducing the cytokine storm. The invention also relates to compound of Formula 1 for use in treating various fibrotic disorders like lung injuries caused by virus or bacterial infections, cardiac, hepatic and kidney fibrosis.

Abstract: Pharmaceutical compositions including an amorphous N—N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.

Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.

Abstract: The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.

Abstract: This invention relates to combination therapies for use in treating cancer, comprising a cyclin dependent kinase 2 (CDK2) inhibitor of Formula (I), as further described herein, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, optionally in further combination with an additional anti-cancer agent=.

Abstract: The present invention relates to c-di-GMP lowering chemical compounds having anti- biofilm properties. In particular, the present invention relates to anti-biofilm compounds or salts or tautomers thereof for use in treatment and/or prevention of bacterial biofilm infection in human subjects caused by biofilm-forming bacteria of the genus Pseudomonas, in particular Pseudomonas spp. including P. aeruginosa. Methods of treating such infections in human subjects are contemplated as well. The present inventions further relates to the use of an anti-biofilm compound or a salt or tautomer thereof for dispersing biofilms in industrial water systems.

Abstract: One aim of the present invention is to treat or prevent chronic heart failure. Provided are: a pharmaceutical composition for treatment or prevention of chronic heart failure, comprising a compound inhibiting SGLT1 or a pharmaceutically acceptable salt thereof; and a method of treating or preventing chronic heart failure, comprising administering a compound inhibiting SGLT1 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to methods of treating specific viral infections using compounds having anti-tubulin or tubulin disruption activity.

Abstract: A single dosage form of pharmaceutical composition for treatment of hypertension and hyperlipidemia is provided. Stability and uniform dissolution rates of drugs may be ensured by mixing compositions containing desired drugs and formulating the mixture into a single compartment form, whereby a manufacturing process becomes simple while reducing processing costs. Further, a formulation having biological equivalence to conventional single formulations may be obtained.

Abstract: A use of a compound or a medicinal derivative thereof in inhibiting absent in melanoma 2 (AIM2) protein activity is provided, and belongs to the field of protein inhibitory medicine technology. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe and stable. Moreover, the compound has a strong binding force with human AIM2 protein and mouse AIM2 protein, and binding constants are as high as 1.029E-5M and 1.033E-5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.

Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

Abstract: Compositions for inhibiting ENPP1 signaling, inactivity, and/or activity are disclosed. The compositions contain a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt thereof. Preferably, the compound binds to the active site of ENPP1 on the extra-cellular domain of ENPP1. Also described are methods of using the compositions. The compounds can be administered via one or more routes of administration to a subject in need thereof. The compounds are present in amounts effective to treat, prevent, or reduce one or more diseases or disorders associated with ENPP1 signaling, inactivity, and/or activity.

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N-R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)1 group (1 is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.

Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as preterm labor at the early gestational stage by the administration of these substances to a patient in need of treatment.

Abstract: The present invention relates to (1R,3S)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compound for use in the treatment of airway diseases, such as allergic asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), obstructive sleep apnea, allergic rhinitis, among others, in subjects having elevated levels of eosinophils in peripheral blood to the use of said compound for the manufacture of a medicament for the treatment of airway diseases, such as allergic asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), obstructive sleep apnea, allergic rhinitis, among others, in subjects having elevated levels of eosinophils in peripheral blood and to a method the treatment of airway diseases, such as allergic asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), obstructi

Abstract: The present disclosure relates to the field of cancer and tumor therapeutics.

Abstract: The present disclosure provides medicaments and methods for the preventive treatment of migraine, particularly the preventive or prophylactic treatment of chronic migraine.

Abstract: Provided herein are methods for treating metastasis of a cancer with a pharmaceutical composition comprising an effective amount of a cathepsin C (CTSC) inhibitor. The CTSC inhibitor, in some embodiments, is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for example, brensocatib. The treatment methods inhibit, slow, or reverse the progression of the metastasis. In some embodiments, the methods further comprise reducing neutrophil infiltration and/or formation of neutrophil extracellular traps (NETs).

Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, tinea versicolor, pityriasis versicolor, tinea circinata, tinea pedis, tinea unguium, tinea manus, tinea cruris, tinea corporis, tinea faciei, tinea capitis, and/or tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

Abstract: The first aspect of the present invention relates to an ophthalmic composition comprising (A) one or more kinds selected from the group consisting of terpenoid, a tocopherol, and a benzyl ammonium compound and a salt thereof, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin. The second aspect of the present invention relates to an ophthalmic composition comprising (A2) a surface active component and (B2) a buffer, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.

Abstract: The present invention relates to a compound selected from mepyramine, prodrugs thereof and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, for use in the topical treatment and prevention of neuropathic pain.

Abstract: The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.

Abstract: The disclosure is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit modified release properties when administered as either whole or half tablets. In particular, the disclosure is directed to modified release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The disclosure is also directed to methods of making and using the same.

Abstract: The present invention relates to combination therapies for treating cancer, in particular a multityrosine kinase-associated cancer. The present invention provides therapeutically effective combinations of: a) N-(3-Fluoro-4-(2-(5-((2-methoxyethylamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy) phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (aka sitravatinib); plus b) a PD-(L)1/PD-1 checkpoint inhibitor; and/or c) the Nectin-4 directed antibody-drug conjugate; as well as methods of using these combinations to treat cancer.

Abstract: The use of inhibitors upstream of mTOR in the CSF1 pathway of neuroinflammation, inhibitors of chemokine receptor CXCR3, functional derivatives thereof, and/or immunosuppressant drugs to reduce neuroinflammation are disclosed. The inhibitors and/or immunosuppressant drugs can treat genetic or environmental encephalopathies and/or reduce microglial activation. Treated encephalopathies include Leigh Syndrome and Wernicke encephalopathy.

Abstract: The present invention relates to a product containing Miglustat alone, or to a combination product containing parenteral Trehalose and oral Miglustat, for treating lysosomal diseases such as the CLN3 disease.

Abstract: Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-naïve Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.

Abstract: Disclosed are methods of for the preventative treatment of migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.

Abstract: The present disclosure relates to dosing regimens comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds or pharmaceutical compositions, pharmaceutical formulations, or combinations comprising the same; and methods of using such compounds, combinations, and compositions in the treatment or prevention IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders or where reduction of IKZF2 or IKZF4 protein levels can ameliorate a disease, for example, the treatment of cancers.

Abstract: Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containg the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

Abstract: An eye-soothing externally-applied liquid medicine includes a phase A, a phase B, an adjuvant and purified water. The phase A includes a western medicine component and a traditional Chinese medicine component by mass. The western medicine component includes at least one of 0.1 g of atropine, 0,1 g of homatropine, and 0.1 g of tropicamide. The traditional Chinese medicine component includes at least one of 0.5 g of a cassia seed extract, 0.5 g of a mulberry leaf extract, 0.2 g of a marigold flower extract, 0.5 g of a fibs albiziae extract, 0.5 g of an eyebright extract, and 0.2 g of a common foxglove leaf extract. The phase B includes 1 g of vitamin A, 0.5 g of vitamin B1, 0.005 g of vitamin B2, 0.001 g of vitamin B12, 0.5 g of adenosine triphosphate, 1 g of vaccinium myrtillus seed oil, and 0.001 g of lutein.

Abstract: A use of anisodamine or a pharmaceutically acceptable salt thereof in the preparation of a cellular glycocalyx protectant and a use of the anisodamine or the pharmaceutically acceptable salt thereof as a cellular glycocalyx protectant in the restoration and protection of cellular glycocalyx and a cell adhesion junction are provided. The use of the anisodamine or the pharmaceutically acceptable salt thereof in the preparation of cellular glycocalyx protectant also has an effect of protecting the structure and function of an endothelial cell.

Abstract: In certain embodiments, the present disclosure relates to compositions comprising a compound that modulates the activity of microsomal triglyceride transfer protein (MTP), and therapeutic methods of using such compositions.